TIGIT Antibody [2D7] Cat. No.: SD8830

Availability: In stock

$0.00

 Price Options

* Required Fields

$0.00
psi-iconSpecifications
HOST SPECIES:Llama
SPECIES REACTIVITY: Human
IMMUNOGEN: TIGIT antibody was raised against a recombinant protein corresponding to amino acids 22-141 of human TIGIT.
TESTED APPLICATIONS: ELISA, Flow, ICC, IF, IHC-P
APPLICATIONS: TIGIT antibody can be used for ELISA starting at 0.1 μg/mLimmunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL. For flow cytometry at 1 μg/ml. For immunocytochemistry at 10μg/mL.
PREDICTED MOLECULAR WEIGHT: Predicted: 26 kDa

psi-iconProperties
PURIFICATION:TIGIT Antibody is affinity chromatography purified via Nickel column. Antibody is supplied as a His-tagged purified protein.  It also contains a myc-tag for detection.
CLONALITY:Monoclonal
ISOTYPE:sdAb
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:TIGIT Antibody is supplied in PBS.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:TIGIT antibody should be stored in working aliquots at -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

psi-iconAdditional Info
OFFICIAL SYMBOL:TIGIT
ALTERNATE NAMES:TIGIT Antibody: T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3, WUCAM
ACCESSION NO.:NP_776160
PROTEIN GI NO.:256600228
GENE ID:2016332
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:TIGIT Antibody: The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1). Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2).
REFERENCES:1) Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106:17858-63.
2) Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26:923-37.

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.